Perry J. Sternberg Joins Sydnexis as Chief Executive Officer

Sydnexis has announced the appointment of Perry J. Sternberg as Chief Executive Officer and a member of the Board of Directors.

Mr. Sternberg is a pharma/biotech executive with more than 30 years in the industry and 15 years in eye care. Immediately prior to joining Sydnexis, he served as President and CEO of Corium LLC. 

“Perry’s appointment comes at a pivotal time for Sydnexis as we continue to advance our lead asset, SYD-101, to slow the progression of pediatric myopia and the risk of associated co-morbidities,” Jeffry Weinhuff, Managing Partner at Visionary Venture Fund and Lead Board Director at Sydnexis, said in a company news release. “Perry has deep expertise in commercialization of new therapies across diverse markets and extensive experience leading organizational growth and transformation. He will be a tremendous asset to Sydnexis.”

Mr. Sternberg brings to Sydnexis more than 30 years of commercial leadership, including oversight of more than 20 product launches across a wide range of therapeutic areas and markets. His tenure in eye care spans 15 years across Novartis, Bausch & Lomb, and Shire, where he was responsible for the US commercial organization and managing the company’s product portfolio in five franchises, which generated nearly $10 billion of revenue annually. He led the build-out of the ophthalmic business unit and launch of dry eye drug Xiidra in 2016.

“The Sydnexis team has an industry-leading track record in eye care. I am excited to join and work with Patrick Johnson, President, and the rest of the management team,” Mr. Sternberg said in the news release. “Progression of pediatric myopia is a serious condition with significant, growing unmet need and no FDA-approved pharmacological treatment options. I look forward to collaborating with this talented team to bring such an innovative treatment option like SYD-101 to pediatric patients, their families, and clinicians.”

Mr. Sternberg will join Sydnexis on August 5.